Aadi Bioscience

Aadi Bio, part of Kaken Group, develops precision oncology therapies targeting signaling pathways in genetically-defined cancers using nanoparticle delivery.

[Aadi Bioscience @aadibio]

In 2025, Aadi Bioscience became a wholly-owned subsidiary of KAKEN Pharmaceutical Co., Ltd. For more information, please visit https://t.co/EljLTKne5E. Follow us for updates on our latest innovations and activities💁‍♀️💊✨

[Aadi Bioscience @aadibio]

Next week, members of our management team will attend the TD Cowen’s 45th Annual Healthcare Conference.  Our President & CEO, Dave Lennon, PhD, will present an overview of our company on Mar. 3.

Tune in here: https://t.co/WBhOlRHFhV
Read more here: https://t.co/yc3begFysV

[Aadi Bioscience @aadibio]

Welcome David Dornan, PhD, to our leadership team!

Dr. Dornan brings deep expertise in antibody-drug conjugates (ADCs) & targeted cancer therapies. We look forward to his contributions as we seek to rapidly advance our newly in-licensed ADC portfolio.

https://t.co/BemCrQn5ry

[Aadi Bioscience @aadibio]

@aadibio is delighted to welcome Baiteng Zhao to our Board!

Dr. Zhao co-founded ProfoundBio, a clinical stage next-gen ADC developer, in 2018 & served as the Chairman and CEO until it was acquired by Genmab for $1.8 billion in May 2024.

[Aadi Bioscience @aadibio]

Today, we announced proposed transactions with the potential to transform @aadibio. Read more here: https://t.co/lXADMTvodh

[Aadi Bioscience @aadibio]

Today, we announce our 2nd quarter 2024 financial results and corporate update. Read more here: https://t.co/TGHWUUICiD

#aadibio $AADI

[Aadi Bioscience @aadibio]

Meet Jill Gaither, our Regional Business Manager since January 2022. Jill focuses on relationship building with Sarcoma Centers of Excellence in the Central region, with the ultimate goal of ensuring MDs & patients have the best possible experience with @Aadibio & our treatment.

[Aadi Bioscience @aadibio]

Join us for our 2nd quarter 2024 earnings conference call scheduled for Wednesday, August 7, 2024, at 8:30am ET.

Click here to register: https://t.co/8y0yNuz4Fo

Click here to read more: https://t.co/rlGidnDGKD

[Aadi Bioscience @aadibio]

Meet Marcus Fairly, our Director of GMP Quality Assurance at @AadiBio. He’s an integral part of our “small but mighty” operations team, responsible for managing Quality Operations, including oversight and execution of multiple functions.

#aadi #employeespotlight

[Aadi Bioscience @aadibio]

Malignant PEComa is among the rarest sarcoma types, and frequently hides in plain sight— which may lead to misdiagnosis and potential suboptimal treatment.

#SarcomaAwarenessMonth

[Aadi Bioscience @aadibio]

Today is Malignant PEComa Day, a special and important moment during Sarcoma Awareness Month specifically dedicated to bringing attention to this aggressive and rare soft tissue sarcoma.

#PEComaAwarenessDay #SarcomaAwarenessMonth

[Aadi Bioscience @aadibio]

Meet Swetha Patel, a Senior Project Manager with @aadibio. Swetha has a critical role in enhancing the efficiency & effectiveness of our clinical programs by identifying & implementing process enhancements and providing essential cross-functional support.
#aadi #employeespotlight

[Aadi Bioscience @aadibio]

@aadibio proudly recognizes Sarcoma Awareness Month – an opportunity to improve understanding of this rare cancer and help people get the diagnosis and treatment they need.

#SarcomaAwarenessMonth

[Aadi Bioscience @aadibio]

Tune in next week for a fireside chat with our President & CEO, Dave Lennon, Ph.D., at the #JefferiesHealthcare Conference! A live webcast of the event, being held on June 5th at 2 pm EDT, will be available on our website: https://t.co/kj93LqW0nr

https://t.co/Og04uEMldE

[Aadi Bioscience @aadibio]

Our goal is to unlock the power of mTOR inhibition by combining nanoparticle albumin bound (nab) technology with sirolimus to improve delivery, stability, solubility & targeting. For #ASCO24, new nonclinical data demonstrate preferential tumor uptake of nab-sirolimus.

[Aadi Bioscience @aadibio]

Join us on May 29th at 3:00 pm ET at the upcoming TD Cowen's 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA for an engaging fireside chat with Dave Lennon, President and CEO of @AadiBio.

Register here! https://t.co/C86lfIdq6I

#aadibio #TDCowenHealthCare

[Aadi Bioscience @aadibio]

Today, we announce our 1st quarter 2024 financial results and corporate update.

Read more here: https://t.co/4WNhFnomh9.

#aadibio $AADI

[Aadi Bioscience @aadibio]

Join us for our 1st quarter 2024 earnings conference call scheduled for Wednesday, May 8th at 8:30am ET.

Read more here: https://t.co/jQ7B8qhwiu

[Aadi Bioscience @aadibio]

The @Aadibio team is pleased to be in San Diego at #AACR24! We will present two posters with new non-clinical data that highlight the combinability of nab-sirolimus.

Hope to see you there!

[Aadi Bioscience @aadibio]

#SG02024 is here! @aadibio will deliver an oral presentation with subgroup analysis data from our AMPECT trial and additional data in three posters that highlight nab-sirolimus as a potential approach for mTOR-driven gynecologic cancers. 

Read more here: https://t.co/e8PPlpjkgo